SCHEMBL3741638

SCHEMBL3741638

CC1CCCCN1C(=O)CC(=O)CCC1CCCC1

nearest known ligand 0.50

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
HPGD P15428 2/20 0.45
SMN1; SMN2 Q16637 1/20 0.45
GAA P10253 3/20 0.43
ALDH1A1 P00352 3/20 0.43
HSD11B1 P28845 1/20 0.42
KMT2A Q03164 2/20 0.42
ATM Q13315 1/20 0.41
TP53 P04637 1/20 0.41
CHRM2 P08172 1/20 0.41
CHRM4 P08173 1/20 0.41
CHRM1 P11229 1/20 0.41
CHRM3 P20309 1/20 0.41
MEN1 O00255 1/20 0.40
LMNA P02545 1/20 0.39
TSHR P16473 1/20 0.39
NPSR1 Q6W5P4 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13041390 0.81 HPGD (0.49) HPGDSMN1; SMN2GAAALDH1A1KMT2A
SCHEMBL3744818 0.79 L3MBTL1 (0.45) HPGDSMN1; SMN2KMT2ATP53MEN1
SCHEMBL11214579 0.77 HPGD (0.51) HPGDSMN1; SMN2GAAALDH1A1KMT2A
SCHEMBL15119952 0.76 HPGD (0.51) HPGDSMN1; SMN2GAAALDH1A1KMT2A
SCHEMBL13041417 0.76 HPGD (0.43) HPGDSMN1; SMN2GAAALDH1A1KMT2A
SCHEMBL3735195 0.75 HAO1 (0.46) KMT2AMEN1
SCHEMBL11892712 0.74 HPGD (0.51) HPGDSMN1; SMN2GAAALDH1A1KMT2A
SCHEMBL13412867 0.74 HPGD (0.51) HPGDSMN1; SMN2GAAALDH1A1KMT2A
SCHEMBL12224346 0.73 HPGD (0.54) HPGDSMN1; SMN2GAAALDH1A1KMT2A
SCHEMBL8459065 0.73 HPGD (0.54) HPGDSMN1; SMN2GAAALDH1A1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100280034-A1 Modulation of pathogenicity QUONOVA, LLC 2010-11-04 US disclosed
US-20100280034-A1 Modulation of pathogenicity QUONOVA, LLC 2010-11-04 US disclosed
US-20100280034-A1 Modulation of pathogenicity QUONOVA, LLC 2010-11-04 US disclosed
US-7338969-B2 Modulation of pathogenicity QUONOVA, LLC (US) 2008-03-04 US disclosed
US-7338969-B2 Modulation of pathogenicity QUONOVA, LLC (US) 2008-03-04 US disclosed
US-7338969-B2 Modulation of pathogenicity QUONOVA, LLC (US) 2008-03-04 US disclosed
US-20070208012-A1 Modulation of Pathogenicity QUONOVA, LLC 2007-09-06 US disclosed
US-20070208012-A1 Modulation of Pathogenicity QUONOVA, LLC 2007-09-06 US disclosed
US-20070208012-A1 Modulation of Pathogenicity QUONOVA, LLC 2007-09-06 US disclosed
US-20070203128-A1 Modulation of Pathogenicity QUONOVA, LLC 2007-08-30 US disclosed
US-20070197492-A1 Modulation of Pathogenicity QUONOVA, LLC 2007-08-23 US disclosed
US-20070184014-A1 Modulation of Pathogenicity QUONOVA, LLC 2007-08-09 US disclosed
US-20070184014-A1 Modulation of Pathogenicity QUONOVA, LLC 2007-08-09 US disclosed
US-20070184014-A1 Modulation of Pathogenicity QUONOVA, LLC 2007-08-09 US disclosed
US-20070093534-A1 Modulation of Pathogenicity QUONOVA, LLC 2007-04-26 US disclosed
US-20070093534-A1 Modulation of Pathogenicity QUONOVA, LLC 2007-04-26 US disclosed
US-20070093534-A1 Modulation of Pathogenicity QUONOVA, LLC 2007-04-26 US disclosed
EP-1622890-A2 BLOCKERS OF THE QUORUM SENSING SYSTEM OF GRAM-NEGATIVE BACTERIA 4SC AG (DE) 2006-02-08 EP disclosed
US-20040235914-A1 Modulation of pathogenicity 4 SC AG (DE) 2004-11-25 US disclosed
WO-2004099175-A2 BLOCKERS OF THE QUORUM SENSING SYSTEM OF GRAM-NEGATIVE BACTERIA 4SC AG (DE) 2004-11-18 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070197492-A1 Modulation of Pathogenicity ANTXR2, Q6ZSR9, PGLS HPGD 2311/4885SMN1; SMN2 4710/4885GAA 1257/4885
US-20070203128-A1 Modulation of Pathogenicity ANTXR2, Q6ZSR9, PGLS HPGD 2311/4885SMN1; SMN2 4710/4885GAA 1257/4885
US-20070093534-A1 Modulation of Pathogenicity NR1H4, NR1I3, NR1H2 HPGD 3338/4885SMN1; SMN2 1924/4885GAA 4098/4885
US-20040235914-A1 Modulation of pathogenicity Q6ZSR9, CCL11, CFH HPGD 3364/4885SMN1; SMN2 2469/4885GAA 2380/4885
US-20070208012-A1 Modulation of Pathogenicity ANTXR2, Q6ZSR9, PGLS HPGD 2311/4885SMN1; SMN2 4710/4885GAA 1257/4885
US-20100280034-A1 Modulation of pathogenicity NR1H4, NR1I3, NR1H2 HPGD 3338/4885SMN1; SMN2 1924/4885GAA 4098/4885
US-20070184014-A1 Modulation of Pathogenicity ANTXR2, Q6ZSR9, PGLS HPGD 2311/4885SMN1; SMN2 4710/4885GAA 1257/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.